Skip to content
Bored Studies
Recruiting

Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

Uromedica · NCT04248283

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 22+ · Women only
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
167
US sites recruiting
4
Study start
January 26, 2021
Record last updated
October 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.

Being studied: Adjustable Continence Therapy for Women (ACT)

Conditions: Urinary Incontinence; Urinary Incontinence,Stress

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Female at least 22 years old
  • Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency
  • Provocative pad weight of greater than 11.0 grams
  • Candidate for surgical intervention
  • Negative urinalysis
  • Normal cystourethroscopy
  • Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)
  • Willing and able to sign informed consent and comply with trial follow-up requirements

Exclusion Criteria

  • Pregnant or lactating
  • Life expectancy of less than 5 years
  • Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL
  • Has auto-immune disease
  • Undergoing radiation therapy
  • Active urinary tract infection
  • Detrusor instability refractory to medication
  • Reduced bladder compliance as defined by a cystometrogram
  • Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml
  • Has, had, or is suspected of having bladder cancer
  • History of bladder stones
  • Urethral stricture evidenced during cystourethroscopy
  • Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
  • Has a diathesis, hemophilia, or a bleeding disorder
  • Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher
  • Had prior pelvic radiotherapy
  • Had a prior artificial urinary sphincter implanted
  • Has a neurogenic condition known to affect bladder/sphincter function

Recruiting US locations

  • University of Colorado

    Denver, CO 80045

    Site contact: Andrea Pina · andrea.pinalimones@cuanschutz.edu

  • Idaho Urologic Institute, PA

    Meridian, ID 83642

    Site contact: Karrie Fox · karried@idurolog.com

  • CHI Health Research Center

    Omaha, NE 68124

    Site contact: Jodi Salvatori, RN, BSN · 402-343-8511 · jodi.salvatori@commonspirit.org

  • Penn State University

    Hershey, PA 17033

    Site contact: Jocelyn Chavla · jchavla@pennstatehealth.psu.edu

Study contacts (from the official record)

  • Lisa Draper · 612-834-7494 · USLDR@COLOPLAST.COM
  • Matt Kelly, PhD · 612-469-8882 · usmtk@coloplast.com
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI (NCT04248283) | Bored Studies